New Research Published In Oncotarget Shows Inhibition Of miR-10b With MN-anti-miR10b Nanodrug Targets Stem Cell-Like Properties In Metastatic Breast Cancer, Reducing Stemness And Preventing Metastasis In Mouse Models When Combined With Chemotherapy
Portfolio Pulse from Benzinga Newsdesk
A new study published in Oncotarget reveals that the MN-anti-miR10b nanodrug can inhibit miR-10b, targeting stem cell-like properties in metastatic breast cancer. This approach reduces stemness and prevents metastasis in mouse models when combined with chemotherapy.
August 28, 2024 | 6:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The study highlights the potential of MN-anti-miR10b nanodrug in treating metastatic breast cancer by inhibiting miR-10b, which could be significant for RNAZ if they are involved in this research or product development.
The research demonstrates a promising new treatment approach for metastatic breast cancer, which could benefit RNAZ if they are associated with the development or commercialization of the MN-anti-miR10b nanodrug. This could lead to increased investor interest and potential stock price appreciation.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80